Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

IL-18 in Blood Serum of Hepatitis C Patients Might be of Predictive Value for Individual Outcomes

Author(s): Morvarid Asadipour, Pooria Fazeli, Mahshid Zohouri, Peyman Bemani, Mohsen Mohebbiniya, Soolmaz Khansalar, Mohammad Reza Fattahi and Kurosh Kalantar*

Volume 21, Issue 3, 2021

Published on: 07 July, 2020

Page: [389 - 393] Pages: 5

DOI: 10.2174/1871526520666200707113401

Price: $65

Abstract

Objective: Pro- inflammatory cytokines including Interleukin (IL)-18 have been shown to be involved in the clearance of Hepatitis C virus (HCV) infection. However, changes in the balance of pro- and anti-inflammatory cytokines production during the immune response, can elicit a variety of liver damages. Therefore, it is of interest to study IL-18 serum levels in hepatitis patients and its correlation with HCV infection.

Methods: Twenty-nine newly diagnosed HCV+ patients with no history of antiviral therapy, and 17 healthy controls, were enrolled in our study. Biochemical markers of liver disease were evaluated by biochemistry assay kits. Serum concentrations of IL-18 were determined with the ELISA method before and after treatment with pangenotypic direct-acting antivirals (DAAs) treatment.

Results: Our results showed statistically significant difference in serum levels of IL-18 in HCV+ patients (692.261 ± 48.76) compared to healthy controls (520.00 ± 44.73) (P=0.021). However, there was no significant difference in IL-18 serum levels between the treated group compared to untreated patients (P=0.74). No significant correlations were detected between the level of IL-18 and liver enzyme levels.

Conclusion: According to our study, IL-18 might be a disease marker associated with HCV infection; however, this conclusion requires further investigation.

Keywords: Hepatitis C, interleukin-18, inflammatory cytokines, direct-acting antivirals (DAAs), liver Enzymes, liver Damage.

Graphical Abstract

[1]
Stanaway, J.D.; Flaxman, A.D.; Naghavi, M.; Fitzmaurice, C.; Vos, T.; Abubakar, I.; Abu-Raddad, L.J.; Assadi, R.; Bhala, N.; Cowie, B.; Forouzanfour, M.H.; Groeger, J.; Hanafiah, K.M.; Jacobsen, K.H.; James, S.L.; MacLachlan, J.; Malekzadeh, R.; Martin, N.K.; Mokdad, A.A.; Mokdad, A.H.; Murray, C.J.L.; Plass, D.; Rana, S.; Rein, D.B.; Richardus, J.H.; Sanabria, J.; Saylan, M.; Shahraz, S.; So, S.; Vlassov, V.V.; Weiderpass, E.; Wiersma, S.T.; Younis, M.; Yu, C.; El Sayed Zaki, M.; Cooke, G.S. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet, 2016, 388(10049), 1081-1088.
[http://dx.doi.org/10.1016/S0140-6736(16)30579-7] [PMID: 27394647]
[2]
Manns, M.P.; Buti, M.; Gane, E.; Pawlotsky, J-M.; Razavi, H.; Terrault, N.; Younossi, Z. Hepatitis C virus infection. Nat. Rev. Dis. Primers, 2017, 3, 17006-17006.
[http://dx.doi.org/10.1038/nrdp.2017.6] [PMID: 28252637]
[3]
Pol, S.; Lagaye, S. The remarkable history of the hepatitis C virus. Genes Immun., 2019, 20(5), 436-446.
[http://dx.doi.org/10.1038/s41435-019-0066-z] [PMID: 31019253]
[4]
Global hepatitis report 2017. Geneva: World Health Organization., 2017. Licence: CC BY-NC-SA 3.0 IGO
[5]
Mahmud, S.; Akbarzadeh, V.; Abu-Raddad, L.J. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Sci. Rep., 2018, 8(1), 150-150.
[http://dx.doi.org/10.1038/s41598-017-18296-9] [PMID: 29317673]
[6]
Dustin, L.B. Innate and adaptive immune responses in chronic HCV infection. Curr. Drug Targets, 2017, 18(7), 826-843.
[http://dx.doi.org/10.2174/1389450116666150825110532] [PMID: 26302811]
[7]
Koziel, M.J. Cytokines in viral hepatitis. Semin. Liver Dis., 1999, 19(2), 157-169.
[http://dx.doi.org/10.1055/s-2007-1007107] [PMID: 10422198]
[8]
Sharma, A.; Chakraborti, A.; Das, A.; Dhiman, R.K.; Chawla, Y. Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology, 2009, 128(1)(Suppl.), e514-e522.
[http://dx.doi.org/10.1111/j.1365-2567.2008.03021.x] [PMID: 19740312]
[9]
Qian, S.; Golubnitschaja, O.; Zhan, X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J., 2019, 10(4), 365-381.
[http://dx.doi.org/10.1007/s13167-019-00194-x] [PMID: 31832112]
[10]
Yoneda, S.; Umemura, T.; Katsuyama, Y.; Kamijo, A.; Joshita, S.; Komatsu, M.; Ichijo, T.; Matsumoto, A.; Yoshizawa, K.; Ota, M.; Tanaka, E. Nagano Interferon Treatment Research Group. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J. Infect. Dis., 2011, 203(8), 1087-1095.
[http://dx.doi.org/10.1093/infdis/jiq165] [PMID: 21398397]
[11]
Falasca, K.; Ucciferri, C.; Dalessandro, M.; Zingariello, P.; Mancino, P.; Petrarca, C.; Pizzigallo, E.; Conti, P.; Vecchiet, J. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci., 2006, 36(2), 144-150.
[PMID: 16682509]
[12]
Veenhuis, R.T.; Astemborski, J.; Chattergoon, M.A.; Greenwood, P.; Jarosinski, M.; Moore, R.D.; Mehta, S.H.; Cox, A.L. Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Monoinfection. Clin. Infect. Dis., 2017, 64(5), 589-596.
[PMID: 27927859]
[13]
Vecchiet, J.; Falasca, K.; Cacciatore, P.; Zingariello, P.; Dalessandro, M.; Marinopiccoli, M.; D’Amico, E.; Palazzi, C.; Petrarca, C.; Conti, P.; Pizzigallo, E.; Guagnano, M.T. Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann. Clin. Lab. Sci., 2005, 35(4), 415-422.
[PMID: 16254258]
[14]
Manohar, K.; Suneetha, P.V.; Sukriti, ; Pati, N.T.; Gupta, A.C.; Hissar, S.; Sakhuja, P.; Sarin, S.K. Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients. Hepatol. Int., 2009, 3(2), 371-377.
[http://dx.doi.org/10.1007/s12072-009-9127-0] [PMID: 19669363]
[15]
Lee, J.H.; Cho, D.H.; Park, H.J. IL-18 and Cutaneous Inflammatory Diseases. Int. J. Mol. Sci., 2015, 16(12), 29357-29369.
[http://dx.doi.org/10.3390/ijms161226172] [PMID: 26690141]
[16]
Baskic, D.; Vukovic, V.R.; Popovic, S.; Djurdjevic, P.; Zaric, M.; Nikolic, I.; Zelen, I.; Mitrovic, M.; Avramovic, D.; Mijailovic, Z. Cytokine profile in chronic hepatitis C: An observation. Cytokine, 2017, 96, 185-188.
[http://dx.doi.org/10.1016/j.cyto.2017.04.008] [PMID: 28433893]
[17]
Chattergoon, M.A.; Levine, J.S.; Latanich, R.; Osburn, W.O.; Thomas, D.L.; Cox, A.L. High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J. Infect. Dis., 2011, 204(11), 1730-1740.
[http://dx.doi.org/10.1093/infdis/jir642] [PMID: 21984735]
[18]
Mariño, E.; Cardier, J.E. Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-alpha and Fas (CD95). Cytokine, 2003, 22(5), 142-148.
[http://dx.doi.org/10.1016/S1043-4666(03)00150-9] [PMID: 12842762]
[19]
Kish, T.; Aziz, A.; Sorio, M. Hepatitis C in a new era: a review of current therapies. P&T, 2017, 42(5), 316-329.
[PMID: 28479841]
[20]
Organization WH.. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection., 2018.
[21]
Carlin, A.F.; Aristizabal, P.; Song, Q.; Wang, H.; Paulson, M.S.; Stamm, L.M.; Schooley, R.T.; Wyles, D.L. Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection. Hepatology, 2015, 62(4), 1047-1058.
[http://dx.doi.org/10.1002/hep.27971] [PMID: 26147061]
[22]
Fallahi, P.; Ferri, C.; Ferrari, S.M.; Corrado, A.; Sansonno, D.; Antonelli, A. Cytokines and HCV-related disorders. Clin. Dev. Immunol., 2012, 2012, 468107-468107.
[http://dx.doi.org/10.1155/2012/468107] [PMID: 22611419]
[23]
de Souza-Cruz, S.; Victória, M.B.; Tarragô, A.M.; da Costa, A.G.; Pimentel, J.P.D.; Pires, E.F.; Araújo, Lde.P.; Coelho-dos-Reis, J.G.; Gomes, Mde.S.; Amaral, L.R.; Teixeira-Carvalho, A.; Martins-Filho, O.A.; Victória, Fda.S.; Malheiro, A. Liver and blood cytokine microenvironment in HCV patients is associated to liver fibrosis score: a proinflammatory cytokine ensemble orchestrated by TNF and tuned by IL-10. BMC Microbiol., 2016, 16, 3-3.
[http://dx.doi.org/10.1186/s12866-015-0610-6] [PMID: 26742960]
[24]
Jia, H.; Du, J.; Zhu, S.; Ma, Y.; Cai, H. Clinical observation of serum IL-18, IL-10 and sIL-2R levels in patients with chronic hepatitis C pre- and post antiviral treatment. Chin. Med. J. (Engl.), 2003, 116(4), 605-608.
[PMID: 12875732]
[25]
El-Hendawy, G.R.; Salama, A.A.; El-Hamid, A.E.A.; Esmaeel, A.T. Study of interleukin-18 during antiviral therapy for hepatitis C with sofosbuvir, ribavirin, and interferon in Menoufia hospitals. Menoufia Med. J., 2018, 31(3), 762.
[26]
Shrivastava, S.; Mukherjee, A.; Ray, R.; Ray, R.B.; Hepatitis, C. Hepatitis C virus induces interleukin-1β (IL-1β)/IL-18 in circulatory and resident liver macrophages. J. Virol., 2013, 87(22), 12284-12290.
[http://dx.doi.org/10.1128/JVI.01962-13] [PMID: 24006444]
[27]
Murakami, S.; Okubo, K.; Tsuji, Y.; Sakata, H.; Takahashi, T.; Kikuchi, M.; Hirayama, R. Changes in liver enzymes after surgery in anti-hepatitis C virus-positive patients. World J. Surg., 2004, 28(7), 671-674.
[http://dx.doi.org/10.1007/s00268-004-7377-5] [PMID: 15175902]

Rights & Permissions Print Cite
Article Metrics
4
1
© 2024 Bentham Science Publishers | Privacy Policy